Market Place
Sourcing Support
EU OKs paediatric use of Gilead`s Epclusa
01 Sep 2020 //
PHARMATIMES
Gilead Announces Presentation of More Than 40 Abstracts Extensive Liver Disease
25 Aug 2020 //
PRESS RELEASE
AbbVie’s HCV treatment receives first for shorter treatment cycle
30 Sep 2019 //
IN-PHARMATECHNOLOGIST
FDA issues safety warning for newer hepatitis C drugs following patient deaths
28 Aug 2019 //
BIOPHARMADIVE
Particle Sciences Expands Controlled Substance Capabilities
29 May 2019 //
CONTRACT PHARMA
Louisiana picks Gilead to partner on `Netflix` model for hep C
27 Mar 2019 //
FIERCE PHARMA
Japan’s Ministry of Health, Labour and Welfare Approves Gilead’s Epclusa®
08 Jan 2019 //
PRESS RELEASE
AbbVie`s latest hep C push highlights Mavyret`s time-to-cure advantage
13 Dec 2018 //
FIERCE PHARMA
What do Martin Shkreli, Gilead and Takeda have in common?
06 Dec 2018 //
ENDPTS
Express Scripts plans `Flex` formulary focused on authorized generics
14 Nov 2018 //
BIOPHARMA DIVE
Gilead raises outlook despite dip in revenue
26 Oct 2018 //
PHARMA TIMES
Gilead`s subsidiary, Asegua Therapeutics to introduce Epclusa & Harvoni
25 Sep 2018 //
PHARMABIZ
Gilead to Sell Cheaper Versions of Drug That Sparked Cost Debate
25 Sep 2018 //
BLOOMBERG
Gilead Subsidiary to Launch Epclusa and Harvoni
24 Sep 2018 //
Gilead to launch generic versions of its hepatitis drugs
24 Sep 2018 //
FDA Issues 54 New and Revised Product-Specific Guidances
13 Sep 2018 //
RAPS
Gilead loses key patent claims for Sovaldi in China
14 Aug 2018 //
ENDPTS
Two pre-grant patent oppositions filed on Gilead’s Hepatitis C medicines
09 Jul 2018 //
HINDU BUSINESS LINE
Sticker Shock: The Real Cost Of America`s 10 Most Expensive Drugs
26 Jun 2018 //
FORBES
Epclusa`s fast-tracked Chinese approval might be late for Gilead
31 May 2018 //
FIERCE PHARMA
Gilead wins European approval for triple hep C combination Vosevi
25 Oct 2017 //
PMLIVE
Gilead gets its go-ahead for blockbuster hopeful Vosevi
20 Jul 2017 //
FIERCE PHARMA
EMA Recommends New HCV, Cancer and MS Drugs for Approval
24 Jun 2017 //
RAPS
WHO Essential Medicines Update Adds Antibiotic use Framework & HCV & HIV Drugs
06 Jun 2017 //
RAPS
Dr Reddy`s Labs launches generic sofosbuvir & velpatasvir tablets for HCV, India
15 May 2017 //
PHARMABIZ
Natco Pharma launches generic hepatitis C drug in India
08 May 2017 //
BUSINESS-STANDARD
Hetero gets DCGI nod for generic chronic hepatitis C drug
05 May 2017 //
ECONOMIC TIMES
FDA Approves First Hep C Drugs for Kids
07 Apr 2017 //
PHARMAMANUFACTURING
How Gilead (GILD) Just Lost $9 Billion in Market Value This Week
09 Feb 2017 //
BIOSPACE
Value investors pile into Gilead expecting strong long-term growth: report
07 Feb 2017 //
FIERCE PHARMA
Final yes from NICE for Gilead’s Epclusa
26 Jan 2017 //
PHARMATIMES
Two new hepatitis C therapies fast-tracked in Europe
25 Jan 2017 //
PMLIVE
EMA Validates Gilead’s Marketing Authorization Application
21 Jan 2017 //
PRESS RELEASE
Gilead Seeks USFDA Approval for Investigational Single Tablet Regimen
12 Dec 2016 //
PHARMABIZ
Gilead`s R&D Woes Could Make it an Attractive Target for Allergan & Pfizer
18 Nov 2016 //
BIOSPACE
AbbVie`s pan-genotypic hep C prospect shines in trials
14 Nov 2016 //
FIERCE PHARMA
SMC Endorses Use of Five Meds on NHS Scotland
08 Nov 2016 //
PHARMATIMES
Recent Success in HCV Treatment Brings Relief to Patients
07 Nov 2016 //
DRUG DEVELOPMENT
Gilead drops PAH, DKD tests after PhII failure
20 Oct 2016 //
FIERCE BIOTECH
EU clears Gilead’s pan-genotypic hepatitis C therapy
21 Jul 2016 //
PHARMATIMES
